| Literature DB >> 34967386 |
Hong Zhou1, Lihong Liu2, Xiao Sun3, Huaguang Wang1, Xiaojia Yu1, Ye Su1, Zhaoyuan You4, Zhuoling An1.
Abstract
ABSTRACT: This study aimed to assess the impact of the pharmacist-led intervention on perioperative antibiotic prophylaxis by standardizing the cephalosporin intradermal skin test in the orthopedic department.A pre-and postintervention study was conducted among patients in the Orthopedics Department at the Beijing Chao-Yang Hospital in China. Use of intradermal skin test, perioperative antibacterial prophylaxis, and cost of care were compared between the preintervention population (admitted from 6/1/2018 to 8/31/2018) and postintervention population (admitted from 1/1/2019 to 3/31/2019). Logistic regression and generalized linear regression were used to assess the intervention impact.425 patients from the preintervention period and 448 patients from the postintervention period were included in the study. After the implementation of the pharmacist intervention program, there was a decrease in the utilization of intradermal skin tests, from 95.8% to 16.5% (P < .001). Patients were more likely to have cephalosporin as prophylactic antimicrobials (OR = 5.28, P < .001) after the implementation. The cost of antimicrobials was significantly reduced by $150.21 (P < .001) for each patient.Pharmacist-involved intervention can reduce the utilization of cephalosporins skin tests and decrease the prescription of unnecessary high-cost antimicrobials.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34967386 PMCID: PMC8718203 DOI: 10.1097/MD.0000000000028458
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.889
Figure 1Intervention Flow Chart.
Demographic and procedural data by pre- and postintervention groups.
| Characteristics | Preintervention (n = 425) | Postintervention (n = 448) |
|
| Female, frequency (%) | 224 (57.4%) | 239 (53.3%) | .247 |
| Age, mean (SE) | 52.4 (0.897) | 58.0 (0.824) | .047 |
| Type of procedure, frequency (%) | <.001 | ||
|
| 159 (37.4%) | 184 (41.1%) | |
|
| 105 (24.7%) | 91 (20.3%) | |
|
| 103 (24.2%) | 97 (21.7%) | |
|
| 27 (6.4%) | 16 (3.6%) | |
|
| 22 (5.2%) | 12 (2.7%) | |
|
| 9 (2.1%) | 41 (9.2%) | |
|
| 0 (0%) | 7 (1.6%) | |
| Length of stay | 11.47 (0.332) | 11.01 (0.283) | .293 |
| CMI, mean (SE) | 1.50 (0.034) | 1.55 (0.033) | .317 |
Allergic data pre-and postintervention.
| Preintervention (n = 425) | Postintervention (n = 448) | |
| Previous allergic disease history | ||
| Asthma | 7 (1.6%) | 2 (0.4%) |
| Allergic rhinitis | 0 (0.0%) | 2 (0.4%) |
| Urticaria | 1 (0.2%) | 1 (0.2%) |
| Anaphylactoid purpura | 0 (0.0%) | 1 (0.2%) |
| Food allergy | 1 (0.2%) | 1 (0.2%) |
| Previous drug allergic history | ||
| Penicillins | 25 (5.9%) | 17 (3.8%) |
| Sulfonamides | 10 (2.4%) | 15 (3.3%) |
| Cephalosporins | 3 (0.7%) | 5 (1.1%) |
| Tetanus antitoxin | 2 (0.5%) | 2 (0.4%) |
| Chinese patent medicine | 2 (0.5%) | 0 (0.0%) |
| SMZCo | 1 (0.2%) | 0 (0.0%) |
| Macrolides | 1 (0.2%) | 1 (0.2%) |
| Furazolidone | 0 (0.0%) | 1 (0.2%) |
| Metoclopramide | 1 (0.2%) | 1 (0.2%) |
| Ephedrine | 1 (0.2%) | 0 (0.0%) |
| Nitroglycerin | 1 (0.2%) | 0 (0.0%) |
| Iodine | 1 (0.2%) | 0 (0.0%) |
| Alcohol | 0 (0.0%) | 2 (0.4%) |
Intradermal skin test, perioperative antibacterial prophylaxis, and cost data pre-and postintervention.
| Preintervention (n = 425) | Postintervention (n = 448) |
| |
| Patients with intradermal skin test | 407 (95.8%) | 74 (16.5%) | <.001 |
| POABP | <.001 | ||
| Cephalosporin | 355 (83.5%) | 433 (96.6%) | <.001 |
| Vancomycin | 36 (8.5%) | 7 (1.6%) | <.001 |
| Clindamycin | 28 (6.6%) | 4 (0.9%) | <.001 |
| Levofloxacin | 6 (1.4%) | 4 (0.9%) | .537 |
| Cost | |||
| Total drugs per patient ($) | 349.2 (191.5, 577.8) | 375.9 (237.6, 567.8) | .211 |
| Antimicrobials per patient ($) | 49.7 (32.1, 82.8) | 44.2 (28.7, 71.6) | .024 |
| Antibiotic cost percentage | 16.8% (11.4%, 25.1%) | 13.8% (8.6%, 21.4%) | <.001 |
Impact of the intervention on intradermal skin test, prophylactic antibiotics, and drug costs.
| Effect size∗ (95% confidence intervals) |
| |
| Patients with intradermal skin tests, OR | 0.008 (0.005, 0.014) | <.001 |
| Cephalosporin as POABP, OR | 5.28 (2.95, 9.43) | <.001 |
| Cost | ||
| Total drugs per patient ($), Coef | –7.34 (–165.61, 150.93) | .928 |
| Antibiotics cost per patient ($), Coef | –150.21 (–225.00, –75.43) | <.001 |
| Antibiotics cost percentage, Coef | –3.2% (–4.7%, –1.7%) | <.001 |